Amgen(AMGN)

THOUSAND OAKS, CABiotechnology3 H-1B visas (FY2023)

View 1,415 open jobs Website LinkedIn Careers Page

Focus: Amgen is a large-cap biotechnology company with $28.2B in annual revenue, specializing in biologics and small molecules across oncology, cardiovascular, bone health, immunology, and neuroscience. The company operates 27,000 employees globally from its Thousand Oaks, CA headquarters and maintains a mature, diversified product portfolio.

Oncology Cardiovascular Bone Health Immunology

Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

27,000

Open Jobs

1415+3610 this month

Hot — 4219 jobs added in 30d

Net +3610 (4219 new, 609 removed). Aggressive expansion phase.

2 recent layoff filings (12 mo) — 100 affected

3/26/2026 — Medford, OR · 78 affected · Layoff
3/9/2026 — 9605 Medical Center Drive, Suite 325 Rockville, MD 20850, MD · 22 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Amgen?

AI assessment

Amgen offers Big Pharma stability, R&D investment, and diversified career paths, but join with awareness of patent cliff vulnerabilities and recent headcount reductions that may offset visible hiring growth.

Why Work Here

Mature company with $28.2B revenue (FY 2025) and strong cash position ($12.0B), providing career stability and investment in R&D ($4.8B annually).

Data completeness

7/9 — Strong

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

4 imminent

CORLANOR

Hiring

Stable

Revenue

$28.2B

FY2025

Key Products

PROLIA

Bone health (RANK Ligand Inhibitor)

$673M Part D

LOE Approaching

Flagship product at 44% of revenue; approaching loss of exclusivity creates critical revenue vulnerability for the company.

Help build intelligence for Amgen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Actively hiring across 1,104 open roles with particular growth in Commercial (256 roles), Engineering (206), and IT (100), signaling expansion despite recent localized layoffs.

Diverse therapeutic portfolio spanning oncology (LUMAKRAS in peak sales), cardiovascular (CORLANOR, PENNSAID), and rare diseases (TEPEZZA) with 30 pipeline programs in Phase 2+, offering broad specialization paths.

Watch Out For

Significant patent cliff exposure: $182M revenue at risk by 2030 (CORLANOR 2027, PENNSAID 2030) with 44% concentration in PROLIA, creating potential restructuring pressure.
Recent workforce reductions: 100 employees laid off in March 2026 (Medford, OR and Rockville, MD), signaling operational efficiency moves despite headline hiring growth.

Generated by Claude from Amgen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

KRYSTEXXA

Gout (uric acid reduction)

$179M Part D

LOE Approaching

Second-largest revenue contributor; specialty indication with limited competition but approaching patent expiration.

LUMAKRAS

Non-small cell lung cancer (KRAS inhibitor)

$140M Part D

Peak14.1yr

Next-generation oncology asset with long patent runway (2040) and strong growth potential in precision medicine segment.

PENNSAID

Actinic keratosis

$135M Part D

Peak4.0yr

Dermatology franchise with 2030 LOE; represents moderate revenue loss risk within next five years.

TEPEZZA

Thyroid eye disease (IGF-1R inhibitor)

$129M Part D

Peak

First-in-class monoclonal antibody for rare orbital disease; demonstrated strong adoption since approval with long-term exclusivity.

RAVICTI

Urea cycle disorder

$73M Part D

Peak5.6yr

Specialty rare-disease therapeutic with modest revenue but strategic value in ultra-orphan segment; LOE 2032.

ARANESP

Anemia (erythropoiesis-stimulating agent)

$60M Part D

LOE Approaching

Legacy biologic asset with declining revenue as biosimilars penetrate market; approaching loss of exclusivity.

CORLANOR

Heart failure (heart rate reduction)

$47M Part D

LOE Approaching0.9yr

Cardiovascular agent with imminent patent expiration (June 2027); first major cliff event in portfolio.

XGEVA

Bone metastases/bone loss (RANK Ligand Inhibitor)

$46M Part D

LOE Approaching

Oncology support therapy utilizing same mechanism as PROLIA; approaching exclusivity loss alongside flagship product.

NEULASTA

Chemotherapy-induced neutropenia (G-CSF agonist)

$42M Part D

LOE Approaching

Oncology supportive care asset facing biosimilar competition; approaching loss of exclusivity with declining revenue trajectory.

Pipeline & Clinical Trials

teprotumumab

Thyroid Eye Disease

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT03461211Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Phase 3

NCT01868997Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Phase 2

NCT02103283A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Phase 1

+2 more

carfilzomib

Multiple Myeloma

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT03934684Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4

NCT03029234Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Anemia

N/A

Clinical Trials (1)

NCT01444456Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

N/A

trifluridine

Mycobacterium Avium-Intracellulare Infection

N/A

Clinical Trials (3)

NCT05198934Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Phase 3

NCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Enbrel®

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00121056REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

N/A

AI-Detected CAC Notification and Care Facilitation

Atherosclerotic Cardiovascular Disease (ASCVD)

N/A

Health Economy Register

Breast Neoplasms

N/A

Clinical Trials (1)

NCT04386629Health Economy Register

N/A

Any treatment for unresectable HCC as chosen by the physician

Carcinoma, Hepatocellular

N/A

Otago Exercise Program

Hip Fractures

N/A

Clinical Trials (1)

NCT04748354Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment

N/A

interferon gamma-1b

HIV Infections

N/A

Clinical Trials (2)

NCT06529731Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

NCT00002433The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During

Chemotherapy-induced Febrile Neutropenia

N/A

Clinical Trials (1)

NCT01813721Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

N/A

Observations

Anemia

N/A

Clinical Trials (1)

NCT00727571LEARN-6™: A Prospective, Observational Nursing Home Study

N/A

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Car

Major Cardiovascular Event

N/A

Clinical Trials (1)

NCT06295679A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

N/A

a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterol

Familial Hypercholesterolemia

N/A

Clinical Trials (1)

NCT03398954a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia

N/A

Pharmacological education

Fracture of Femur

N/A

Clinical Trials (1)

NCT05669040mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health

N/A

Retrospective Chart Review

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00454857Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

N/A

standard care

Hyperparathyroidism, Secondary

N/A

Clinical Trials (3)

NCT01196715Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes

Phase 3

NCT05601492Adherence to Otezla

Phase 1

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

Care Champion Intervention

ASCVD

N/A

Clinical Trials (1)

NCT06471036Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

N/A

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

Cancer

N/A

Clinical Trials (1)

NCT00300001Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

N/A

Osteonecrosis of the Jaw (ONJ) Case Registry

Osteonecrosis of the Jaw

N/A

Clinical Trials (1)

NCT01666106Osteonecrosis of the Jaw (ONJ) Case Registry

N/A

talimogene laherparepvec

Melanoma

N/A

Clinical Trials (5)

NCT01161498Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Phase 3

NCT00769704Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Lung Cancer

N/A

Care Transitions in Renal Disease Patients

Renal Disease

N/A

Clinical Trials (1)

NCT01842776Care Transitions in Renal Disease Patients

N/A

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients

Cystic Fibrosis

N/A

Aranesp

Chronic Kidney Disease, Receiving Dialysis

N/A

Clinical Trials (5)

NCT00111995Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Phase 4

NCT00117039A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pat

Metastatic Colorectal Cancer

N/A

Clinical Trials (1)

NCT02322736Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

N/A

Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthr

Psoriatic Arthritis

N/A

Clinical Trials (1)

NCT01139918Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis

N/A

No Intervention for Observational Study

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00861224Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

N/A

MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

Familial Hypercholesterolemia - Heterozygous

N/A

Clinical Trials (1)

NCT02517944MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

N/A

Not applicable- observational study

Birth Defect

N/A

Clinical Trials (1)

NCT02090088Nplate® Pregnancy Exposure Registry

N/A

MRI

Neuromyelitis Optica Spectrum Disorders

N/A

Clinical Trials (5)

NCT03182699Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients

Phase 4

NCT03783026A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis

Healing Circuits™ sessions

Crohn Disease (CD)

N/A

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Managem

Medical Conditions to be Studied

N/A

Clinical Trials (1)

NCT02993120Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

N/A

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Stud

RAS Wild Type mCRC

N/A

Clinical Trials (1)

NCT02792478Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

N/A

ActiveHip+ mobile application

Hip Fractures

N/A

Clinical Trials (1)

NCT04859309Activating Older People After a Hip Fracture

N/A

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Pa

HIV Seropositivity

N/A

Clinical Trials (1)

NCT03139630COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients

N/A

nonmyeloablative stem cell transplant

Metastatic Solid Tumor

N/A

Clinical Trials (1)

NCT00997529Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors

N/A

therascreen® KRAS RGQ PCR Kit

Colo-rectal Cancer

N/A

Clinical Trials (1)

NCT05347745Therascreen® KRAS RGQ PCR Kit

N/A

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Tra

Hyperparathyroidism

N/A

Clinical Trials (1)

NCT01163669A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients

N/A

Diffusion Weighted Magnetic Resonance Imaging

Myeloma

N/A

Clinical Trials (1)

NCT03951220The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

N/A

OFF in experimental arm

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT00786058A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

N/A

Corrie Lipids Digital Health Program

Cardiovascular Risk

N/A

Dental implant surgery

Missing Teeth

N/A

Clinical Trials (1)

NCT04741906Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication

N/A

Opportunistic screening for low BMD

Low Bone Density

N/A

Clinical Trials (1)

NCT05245851Clinical Deployment and Validation of Rho

N/A

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvM

ASCVD

N/A

Clinical Trials (1)

NCT04197453The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

N/A

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Post-Traumatic Headache

N/A

application

Secondary Prevention

N/A

Clinical Trials (2)

NCT03619993Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

N/A

NCT05542719Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular

N/A

Physician Survey

Solid Tumours

N/A

Clinical Trials (1)

NCT01998607Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw

N/A

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving F

Head and Neck Cancer

N/A

Interview Prep Quick Facts

Founded: 1980

Portfolio: 49 approved products, 160 clinical trials

Top TAs: Oncology, Immunology, Hematology

H-1B (2023): 3 approvals

Publications: 99 in PubMed

SEC Filings: 2 available

Open Roles: 1415 active jobs

Portfolio Health

Launch2 (4%)

Growth5 (10%)

Peak17 (35%)

LOE Approaching17 (35%)

Post-LOE8 (16%)

49 total products

Therapeutic Area Focus

Oncology

22 marketed551 pipeline

Immunology

13 marketed187 pipeline

Hematology

5 marketed83 pipeline

Nephrology

5 marketed82 pipeline

Financials (FY2025)

Revenue

$28.2B7%

R&D Spend

$4.8B(17%)8%

Net Income

$6.7B

Hiring Trend

Actively Hiring

1415

Open Roles

+1071

Added

-197

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2026-03-26

78 employees affected— Medford, OR

2026-03-09

22 employees affected— Rockville, MD

Source: state DOL filings, aggregated via Big Local News

100 employees laid off across Medford, OR (78) and Rockville, MD (22) facilities in March 2026, likely reflecting operational consolidation or clinical trial portfolio optimization.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study.

Hematology (Amsterdam, Netherlands)

2026

PMID:41709689

Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.

mAbINJECTION · INJECTABLE

Tumor Necrosis Factor Receptor Blocking Activity

NCT01302392A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3

NCT00002037Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

N/A

NCT02273570Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

N/A

NCT02366195Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Phase 2

NCT00117117A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Phase 4

NCT02613416Denosumab and MRI Breast Imaging

Phase 2

3 marketed79 pipeline

Endocrinology

2 marketed51 pipeline

Cardiovascular

10 marketed34 pipeline

Neurology

5 marketed30 pipeline

Recent layoffs signal operational restructuring despite positive revenue growth; geographic concentration (Medford, Rockville) suggests targeted function elimination rather than company-wide reduction, mitigating systemic job-loss risk for most job seekers.

The journal of allergy and clinical immunology. Global

2026

PMID:42433269

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Amgen(AMGN)

Should You Work at Amgen?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (30)

Key Products by Revenue

Other Products (11)

Pipeline & Clinical Trials

Recent News · Amgen(10)

Open Jobs (1415)

Competitive Intelligence Senior Manager, Global Biosimilars

Business Architect, Applied AI & Automation

Thought Leader Liaison - Rare Disease (Uplizna) - Michigan

Account Manager / Specialty Account Manager - Tavneos - Oakland, CA

Senior Legal Executive Assistant

Medical Value Access Director - National Accounts, Kaiser

Medical Value Access Director - National Accounts, Humana

Specialty/ Senior Specialty Representative - Dermatology - San Jose, CA

Digital AI Product Analyst

Field Reimbursement Manager - Hartford, CT

Associate Director, Information Systems

AI Digital Product Sr Manager - AI Studio (REMOTE)

Scientific Director

Medical Value Access Liaison - Pittsburgh/Ohio

Medical Value Access Liaison - New York Territory

AI Digital Product Sr Manager – Agentic Platform (REMOTE)

Senior Principal Scientist

Senior Manager, Master Data Management & Reference Data

Field Reimbursement Manager

Account Manager/Specialty Account Manager - TAVNEOS - Kansas City, KS/MO

Quality Compliance, Director

Senior Specialty Representative - Cardiovascular - Tampa South, FL

Specialty Representative/Senior Specialty Representative - Flint, MI

Quality Assurance Specialist - 2nd shift (3pm - 11:30pm)

Principal Scientist – Chemical Biology & Proximity-Based Therapeutics

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)